Mechanisms of Diabetic Nephropathy in Ecuador
NCT02237352 · Status: SUSPENDED · Type: OBSERVATIONAL · Enrollment: 10064
Last updated 2026-05-05
Summary
The prevalence of diabetes mellitus (DM) is increasing worldwide, suggesting that 45% of diabetics are undiagnosed. DM induces a kidney disease called diabetic nephropathy (DN) which is the largest single cause of end-stage renal disease and dialysis requirement. In South America the prevalence of DM and chronic kidney disease has increased, and great disparity exists among countries in regards to access to the dialysis treatment. It has been considerate that Hispanic origin increases the risk for DM. The South Americans have distinctive habits, culture, environment, behavior and genetic background and the factors involved in DN have not been defined yet. The early kidney lesions such as neoangiogenesis (pathologic generation of the new blood vessels) and extracellular matrix expansion have been described. The vascular endothelial growth factor A (VEGF) has been linked to angiogenesis, but the role of VEGF in DN has not been elucidated yet. VEGF signals mainly through VEGF receptor 2 (VEGFR2). VEGFR2 interacts with alphaV beta3 integrin (AVB3) in kidney. Additionally tenascin C is expressed in the extracellular matrix. Tenascin C and the tenascin C/AVB3 complex have also been linked to angiogenesis, however their roles have not been unveiled yet in the DN. Investigators hypothesize that VEGF signaling and tenascin C play an important role in DN and that VEGFR2, AVB3 and tenascin C interact. The purposes of this study is to characterize social, environmental and biological factors implicated in the DN in Ecuador and define the role of VEGF signaling and tenascin C in the pathogenesis of the DN. Investigators propose to study factors involved in DN in diabetic and non-diabetic adults from general population, with and without DN. In a single time investigators will evaluate demographics data, habits, personal and family history through a survey. Investigators will measure anthropometrics parameters and blood pressure; investigators will quantify blood glucose, glycosylated hemoglobin A1c and proteinuria. In addition investigators will examine the role of tenascin C and VEGF signaling by analyzing paraffin embedded kidney tissue, plasma and urine samples. Characterizing the factors involved in the DN from Hispanic people is key to establish adequate strategies of prevention, diagnosis and treatment in this population. Furthermore elucidating the role of proteins involved in DN may offer valuable tools for the development of new treatments.
Conditions
- Diabetic Nephropathy
- Diabetes Mellitus
- Kidney Diseases
- Diabetic Kidney Disease
- Chronic Kidney Disease
Sponsors & Collaborators
-
Secretaría de Ciencia, Tecnología e Innovación (Senescyt)
collaborator UNKNOWN -
PROMETEO
collaborator UNKNOWN -
Universidad Estatal de Milagro
lead OTHER
Principal Investigators
-
Delma Veron, MD PhD · Universidad Estatal de Milagro
Eligibility
- Min Age
- 21 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2014-09-15
- Primary Completion
- 2026-05-01
- Completion
- 2026-05-01
Countries
- Ecuador
Study Locations
More Related Trials
-
Diabetic Patients With End-Stage Renal Disease
NCT00435786 ·Status: COMPLETED
-
Transformative Research in Diabetic Nephropathy
NCT02986984 ·Status: RECRUITING
-
T-regulatory Cells in Diabetic Type Two Nephropathy
NCT03591939 ·Status: UNKNOWN
-
PeRsOnalising Treatment Of Diabetic Nephropathy:
NCT03509454 ·Status: COMPLETED
-
Mechanism of SGLT2 Inhibition in the Kidney
NCT06291155 ·Status: RECRUITING ·Phase: PHASE4
-
Effects of Disease Management on Development of End Stage Renal Disease in Type 2 Diabetic Patients With Nephropathy
NCT00309127 ·Status: COMPLETED ·Phase: NA
-
Effect of Integrated CKD Care Program in Early Diabetic Nephropathy in Primary Health Care Setting.
NCT02194790 ·Status: COMPLETED ·Phase: NA
-
Effects of Fenofibrate Therapy in Diabetic Nephropathy
NCT03869931 ·Status: UNKNOWN ·Phase: PHASE3
-
Renal Mechanism of SGLT2 Inhibition
NCT05507892 ·Status: RECRUITING ·Phase: PHASE2
-
Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes
NCT00976495 ·Status: COMPLETED ·Phase: PHASE2
-
OPTIMISE-CKD Drug Utilization
NCT05932901 ·Status: COMPLETED
-
Kidney Biopsy Indications in Type 2 Diabetes Patients
NCT04006028 ·Status: COMPLETED
-
The Differential Effects of Diabetes Therapy on Inflammation
NCT02150707 ·Status: COMPLETED
-
Nitric Oxide (NO) Activity and Diabetic Nephropathy
NCT00136188 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Therapeutic Drug Use for CKD Patients
NCT05818995 ·Status: UNKNOWN
-
Treating Patients With Renal Impairment and Altered Glucose MetAbolism With TherapeutIc Carbohydrate Restriction and Sglt2-Inhibiton - a Pilot Study
NCT06094231 ·Status: TERMINATED ·Phase: NA
-
Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients
NCT06140537 ·Status: RECRUITING ·Phase: PHASE4
-
Effect of SGLT2 Inhibition on OCT-A Parameters in Diabetic CKD
NCT04215445 ·Status: UNKNOWN ·Phase: PHASE4
-
Mycophenolate Mofetil, Carnitine and PDE5 Inhibitor, Three Potential Treatments for Resistant Proteinuria Slowing Diabetic Nephropathy Deterioration
NCT01566006 ·Status: UNKNOWN ·Phase: NA
-
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
NCT05530356 ·Status: ENROLLING_BY_INVITATION
-
Pharmacogenetics of Ace Inhibitor-Associated Angioedema
NCT01413542 ·Status: COMPLETED ·Phase: NA
-
Matrix Metalloproteinases and Diabetic Nephropathy
NCT00067886 ·Status: COMPLETED
-
Effect of Dorzagliatin on Renal Function Outcomes in People With Type 2 Diabetes: a Multicentric, Prospective, Randomized Study.
NCT06222476 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Prediabetes in End Stage Renal Disease on Dialysis
NCT07337083 ·Status: COMPLETED
-
Association of AGTR1 and ACACB Gene Polymorphism and Diabetic Nephropathy in Type 2 Diabetes
NCT01069549 ·Status: COMPLETED